Next Article in Journal
Alkoxy and Enediyne Derivatives Containing 1,4-Benzoquinone Subunits—Synthesis and Antitumor Activity
Next Article in Special Issue
Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK
Previous Article in Journal
A Model Study of the Photochemical Fate of As(III) in Paddy-Water
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Molecules 2017, 22(3), 446; doi:10.3390/molecules22030446

CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors

1
Section for Hematology, Department of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Bergen 5021, Norway
2
Department of Medicine, Haukeland University Hospital, Bergen 5021, Norway
3
“Drug Discovery” Laboratory, Department of Pharmacy, University of Naples Federico II, Naples 80131, Italy
*
Authors to whom correspondence should be addressed.
Academic Editors: Pierre Koch and Stefan Laufer
Received: 25 January 2017 / Revised: 1 March 2017 / Accepted: 6 March 2017 / Published: 11 March 2017
(This article belongs to the Special Issue Kinase Inhibitors)
View Full-Text   |   Download PDF [11700 KB, uploaded 14 March 2017]   |  

Abstract

Cell division cycle 25 (CDC25) protein phosphatases regulate cell cycle progression through the activation of cyclin-dependent kinases (CDKs), but they are also involved in chromatin modulation and transcriptional regulation. CDC25 inhibition is regarded as a possible therapeutic strategy for the treatment of human malignancies, including acute myeloid leukemia (AML). We investigated the in vitro effects of CDC25 inhibitors on primary human AML cells derived from 79 unselected patients in suspension cultures. Both the previously well-characterized CDC25 inhibitor NSC95397, as well as five other inhibitors (BN82002 and the novel small molecular compounds ALX1, ALX2, ALX3, and ALX4), only exhibited antiproliferative effects for a subset of patients when tested alone. These antiproliferative effects showed associations with differences in genetic abnormalities and/or AML cell differentiation. However, the responders to CDC25 inhibition could be identified by analysis of global gene expression profiles. The differentially expressed genes were associated with the cytoskeleton, microtubules, and cell signaling. The constitutive release of 28 soluble mediators showed a wide variation among patients and this variation was maintained in the presence of CDC25 inhibition. Finally, NSC95397 had no or only minimal effects on AML cell viability. In conclusion, CDC25 inhibition has antiproliferative effects on primary human AML cells for a subset of patients, and these patients can be identified by gene expression profiling. View Full-Text
Keywords: CDC25 inhibitors; acute myeloid leukemia; gene expression; cytogenetics; leukemic cell differentiation CDC25 inhibitors; acute myeloid leukemia; gene expression; cytogenetics; leukemic cell differentiation
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Brenner, A.K.; Reikvam, H.; Rye, K.P.; Hagen, K.M.; Lavecchia, A.; Bruserud, Ø. CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors. Molecules 2017, 22, 446.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top